Detail akcie Virbac SA online

Business Summary: Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Virbac SA revenues increased 12% to EUR1.4B. Net income increased 20% to EUR145.3M. Revenues reflect Africa & Middle East segment increase from EUR29.7M to EUR174.4M, North America segment increase of 10% to EUR181.6M. Net income benefited from Foreign exchange gains and losses decrease of 83% to EUR2.7M (expense), Provisions decrease from EUR1.2M (expense) to EUR860K (income).